HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 167 filers reported holding HALOZYME THERAPEUTICS INC in Q1 2016. The put-call ratio across all filers is 0.15 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $7,177,321 | -3.1% | 187,888 | -8.5% | 0.00% | -33.3% |
| Q2 2023 | $7,406,144 | +8.3% | 205,327 | +14.6% | 0.00% | +50.0% |
| Q1 2023 | $6,840,554 | -18.4% | 179,119 | +21.5% | 0.00% | -33.3% |
| Q4 2022 | $8,386,150 | +331.4% | 147,384 | +199.7% | 0.00% | +200.0% |
| Q3 2022 | $1,944,000 | -44.0% | 49,177 | -37.6% | 0.00% | 0.0% |
| Q2 2022 | $3,471,000 | -4.2% | 78,872 | -13.2% | 0.00% | 0.0% |
| Q1 2022 | $3,625,000 | -48.9% | 90,894 | -48.4% | 0.00% | -50.0% |
| Q4 2021 | $7,090,000 | +7.1% | 176,313 | +8.3% | 0.00% | 0.0% |
| Q3 2021 | $6,623,000 | +75.8% | 162,800 | +96.2% | 0.00% | +100.0% |
| Q2 2021 | $3,768,000 | -44.2% | 82,993 | -48.7% | 0.00% | -50.0% |
| Q1 2021 | $6,747,000 | +46.9% | 161,850 | +50.5% | 0.00% | 0.0% |
| Q4 2020 | $4,593,000 | +148.4% | 107,535 | +52.9% | 0.00% | +100.0% |
| Q3 2020 | $1,849,000 | -80.3% | 70,330 | -79.9% | 0.00% | -75.0% |
| Q2 2020 | $9,396,000 | +309.9% | 350,500 | +175.0% | 0.00% | +300.0% |
| Q1 2020 | $2,292,000 | -52.0% | 127,450 | -52.7% | 0.00% | -50.0% |
| Q4 2019 | $4,774,000 | +42.4% | 269,282 | +24.6% | 0.00% | +100.0% |
| Q3 2019 | $3,352,000 | +44.4% | 216,119 | +59.9% | 0.00% | 0.0% |
| Q2 2019 | $2,321,000 | +76.1% | 135,142 | +65.0% | 0.00% | 0.0% |
| Q1 2019 | $1,318,000 | -55.6% | 81,883 | -59.6% | 0.00% | 0.0% |
| Q4 2018 | $2,966,000 | +67.4% | 202,735 | +107.9% | 0.00% | 0.0% |
| Q3 2018 | $1,772,000 | +56.0% | 97,535 | +44.8% | 0.00% | – |
| Q2 2018 | $1,136,000 | -68.4% | 67,341 | -63.3% | 0.00% | -100.0% |
| Q1 2018 | $3,595,000 | +114.4% | 183,556 | +121.8% | 0.00% | +100.0% |
| Q4 2017 | $1,677,000 | -14.5% | 82,743 | -26.7% | 0.00% | 0.0% |
| Q3 2017 | $1,961,000 | +66.2% | 112,907 | +22.7% | 0.00% | 0.0% |
| Q2 2017 | $1,180,000 | -12.6% | 92,031 | -11.6% | 0.00% | 0.0% |
| Q1 2017 | $1,350,000 | -29.8% | 104,161 | -46.5% | 0.00% | 0.0% |
| Q4 2016 | $1,924,000 | +49.0% | 194,684 | +82.2% | 0.00% | 0.0% |
| Q3 2016 | $1,291,000 | -32.4% | 106,831 | -51.8% | 0.00% | 0.0% |
| Q2 2016 | $1,911,000 | -44.6% | 221,524 | -39.2% | 0.00% | -50.0% |
| Q1 2016 | $3,451,000 | -35.4% | 364,421 | +18.2% | 0.00% | -33.3% |
| Q4 2015 | $5,343,000 | +199.7% | 308,310 | +132.2% | 0.00% | +200.0% |
| Q3 2015 | $1,783,000 | -72.5% | 132,784 | -53.7% | 0.00% | -75.0% |
| Q2 2015 | $6,475,000 | +28.1% | 286,827 | -19.0% | 0.00% | 0.0% |
| Q1 2015 | $5,056,000 | +330.3% | 354,038 | +190.7% | 0.00% | +300.0% |
| Q4 2014 | $1,175,000 | – | 121,771 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Security, LLC | 19,305,403 | $233,209,000 | 10.86% |
| BB BIOTECH AG | 7,379,832 | $89,148,000 | 3.13% |
| SENZAR ASSET MANAGEMENT, LLC | 550,544 | $6,650,572,000 | 1.72% |
| SNYDER CAPITAL MANAGEMENT L P | 2,232,114 | $26,964,000 | 1.69% |
| Sterling Global Strategies LLC | 22,000 | $266,000 | 0.98% |
| IRIDIAN ASSET MANAGEMENT LLC/CT | 9,290,024 | $112,223,000 | 0.98% |
| MSD Partners, L.P. | 965,000 | $11,657,000 | 0.94% |
| DOHENY ASSET MANAGEMENT /CA | 130,950 | $1,582,000 | 0.81% |
| Taylor Wealth Management Partners | 128,110 | $1,548,000 | 0.69% |
| Bellevue Group AG | 318,000 | $3,841,000 | 0.69% |